Registry for patients with myeloid diseases in Austria

Austrian Myeloid Registry

This study collects information from patients with myeloid diseases in Austria to help improve understanding and treatment of conditions like myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Quick facts

• Study type: Observational
• Enrollment: 3000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie (Academic / other)
• Locations: 16 sites (Feldkirch and 15 other locations)
• Trial ID: NCT04438889 on ClinicalTrials.gov

What this trial studies

The Austrian Myeloid Registry (aMYELOIDr) is a non-interventional observational study that collects data from patients diagnosed with myeloid diseases, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). This multi-center registry gathers real-world data from various sites in Austria, with the potential for future expansion to other countries. Data is entered into an electronic case report form (eCRF) by clinical personnel and physicians, aiming to enhance understanding and management of these conditions.

Who should consider this trial

Good fit: Ideal candidates for this registry are individuals over 17 years old diagnosed with a myeloid disease as per WHO 2016 criteria.

Not a fit: Patients who are unable or unwilling to sign informed consent will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the management and treatment outcomes of myeloid diseases, ultimately improving patient care.

How similar studies have performed: Other observational registries have shown success in collecting valuable data for similar conditions, indicating that this approach is promising.

Eligibility criteria

Inclusion Criteria:

* Age \>17 years
* Diagnosis of myeloid disease according to WHO 2016
* Signed patient informed consent (IC)

Exclusion Criteria:

* Patient is unable or unwilling to sign IC

Where this trial is running

Feldkirch and 15 other locations

• LKH Feldkirch, Innere Medizin II, Interne E: Hämatologie und Onkologie — Feldkirch, Austria (Recruiting)
• KH der Barmherzigen Brüder, Innere Medizin I — Graz, Austria (Recruiting)
• Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie — Graz, Austria (Not_yet_recruiting)
• Universitätsklinik Innsbruck, Univ.-Klinik für Innere Medizin V, Hämatologie und Onkologie — Innsbruck, Austria (Recruiting)
• Universitätsklinikum Krems, Innere Medizin II Hämato-Onkologie — Krems, Austria (Recruiting)
• LKH Hochsteiermark, Abteilung für Hämato-Onkologie — Leoben, Austria (Recruiting)
• Ordensklinikum Linz GmbH, Barmherzige Schwestern, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie — Linz, Austria (Recruiting)
• Ordensklinikum Linz GmbH, Elisabethinen, I. Interne Abteilung Hämato-Onkologie — Linz, Austria (Recruiting)
• Kepler Universitätsklinikum Linz, Med. Campus III., Univ.-Klinik für Hämatologie und Internistische Onkologie — Linz, Austria (Recruiting)
• Universitätsklinik für Innere Med. III, PMU Salzburg — Salzburg, Austria (Recruiting)
• Universitätsklinikum St. Pölten, Klinische Abteilung für Innere Medizin 1 — Sankt Pölten, Austria (Recruiting)
• Klinikum Steyr, Innere Medizin II — Steyr, Austria (Recruiting)
• Hanusch KH, 3. Med. Abteilung — Vienna, Austria (Recruiting)
• Klinik Ottakring, 1. Med. Abteilung — Vienna, Austria (Recruiting)
• Klinik Donaustadt: 2. Medizinische Abteilung — Vienna, Austria (Recruiting)
• Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV — Wels, Austria (Recruiting)

Study contacts

• Principal investigator: Lisa Pleyer, MD — 3rd Med Dept Paracelsus Medical University, Salzburg
• Study coordinator: Lisa Pleyer, MD

Conditions Myeloid Diseases; MDS; CMML; AML; PMF; Austrian Myeloid Registry